{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:01:21Z","timestamp":1791378081506,"version":"4.3.2"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008890","name":"University of Dundee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jaci.2022.10.028","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T01:30:33Z","timestamp":1668562233000},"page":"700-705.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-8266","authenticated-orcid":false,"given":"Rory","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"RuiWen Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunny","family":"Jabbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2022.10.028_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.29328\/journal.aaai.1001023","article-title":"A retrospective cohort study to evaluate the relationship of airway hyperresponsiveness to type 2 biomarkers in persistent asthma","volume":"5","author":"Chan","year":"2021","journal-title":"Arch Asthma Allergy Immunol"},{"key":"10.1016\/j.jaci.2022.10.028_bib2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1183\/09031936.03.00008403","article-title":"Indirect airway challenges","volume":"21","author":"Joos","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.10.028_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1378\/chest.11-1748","article-title":"A randomized primary care trial of steroid titration against mannitol in persistent asthma: STAMINA trial","volume":"141","author":"Lipworth","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jaci.2022.10.028_bib4","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1164\/ajrccm.163.7.2010145","article-title":"PC20 adenosine 5\u2032-monophosphate is more closely associated with airway inflammation in asthma than PC20 methacholine","volume":"163","author":"Van Den Berge","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.10.028_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01033-2018","article-title":"ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing","volume":"52","author":"Hallstrand","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.10.028_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2020.06.048","article-title":"Pragmatic clinical perspective on biologics for severe refractory type 2 asthma","author":"Chan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.10.028_bib7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jaci.2019.10.037","article-title":"IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways","volume":"145","author":"Manson","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.10.028_bib8","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1111\/bph.15240","article-title":"Targeting IL-5 pathway against airway hyperresponsiveness: a comparison between benralizumab and mepolizumab","volume":"177","author":"Calzetta","year":"2020","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaci.2022.10.028_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/14656566.2012.638917","article-title":"The use of inhaled mannitol in the diagnosis and management of asthma","volume":"13","author":"Sverrild","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaci.2022.10.028_bib10","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1034\/j.1398-9995.2003.00226.x","article-title":"Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate","volume":"58","author":"Currie","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2022.10.028_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1081-1206(10)61396-8","article-title":"Comparative cutoff points for adenosine monophosphate and methacholine challenge testing","volume":"93","author":"Fardon","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2022.10.028_bib12","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.10.028_bib13","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry, 2019 update. An official American Thoracic Society and European Respiratory Society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.10.028_bib14","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00753-2019","article-title":"Technical standards for respiratory oscillometry","author":"King","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.10.028_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaci.2022.10.028_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.10.028_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaci.2010.08.042","article-title":"Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation","volume":"127","author":"Meltzer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2022.10.028_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.10.028_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01865-2021","article-title":"Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma","author":"Al-Shaikhly","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.10.028_bib20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2222.2003.01688.x","article-title":"Effects of mediator antagonism on mannitol and adenosine monophosphate challenges","volume":"33","author":"Currie","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2022.10.028_bib21","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1172\/JCI126402","article-title":"Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling","volume":"129","author":"Altman","year":"2019","journal-title":"J Clin Invest"},{"issue":"9248","key":"10.1016\/j.jaci.2022.10.028_bib22","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"Leckie","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2022.10.028_bib23","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2022.10.028_bib24","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.jaip.2020.03.035","article-title":"Serum eosinophil-derived neurotoxin better reflect asthma control status than blood eosinophil counts","volume":"8","author":"An","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2022.10.028_bib25","article-title":"Blood eosinophil cationic protein and eosinophil-derived neurotoxin are associated with different asthma expression and evolution in adults","author":"Granger","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jaci.2022.10.028_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1164\/rccm.200208-789OC","article-title":"Eosinophil\u2019s role remains uncertain as anti\u2013interleukin-5 only partially depletes numbers in asthmatic airway","volume":"167","author":"Flood-Page","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2022.10.028_bib27","article-title":"Repeatability of impulse oscillometry in patients with severe asthma","author":"Chan","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.10.028_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.rmed.2019.07.010","article-title":"Scottish consensus statement on the role of FeNO in adult asthma","volume":"155","author":"Kuo","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2022.10.028_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/rmed.2001.1034","article-title":"Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use?","volume":"95","author":"Juniper","year":"2001","journal-title":"Respir Med"},{"key":"10.1016\/j.jaci.2022.10.028_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1034\/j.1399-3003.1999.14a08.x","article-title":"Development and validation of the Mini Asthma Quality of Life Questionnaire","volume":"14","author":"Juniper","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaci.2022.10.028_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1399-3003.1999.14a06.x","article-title":"What are minimal important changes for asthma measures in a clinical trial?","volume":"14","author":"Santanello","year":"1999","journal-title":"Eur Respir J"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492201510X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492201510X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:42:30Z","timestamp":1758793350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492201510X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S009167492201510X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2022.10.028","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2022.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}